Obesity protocols rarely fail because sponsors cannot find patients. They fail because the right patients are harder to identify than the topline prevalence suggests, and because screening, diversity targets, and retention pressure all land at the same time. That reality is pushing more teams to specialist partners in obesity clinical trial recruitment instead of relying on generic outreach playbooks.

Below is a list of the Top 10 Best Obesity Clinical Trial Recruitment Companies 2026, highlighting what sets each company apart. By understanding what makes each company unique, you will have a better idea of which ones is the best fit for the needs of your specific trial.

‍

The Top 10 Best Obesity Clinical Trial Recruitment Companies 2026

1. Patiro

Patiro offers global full-service and FSP solutions for obesity, metabotlic disease, and GLP-1 clinical trial recruitment, and covers everything from outreach and prequalification to site coordination and retention support. Local medical teams conduct 1-on-1 pre-screening in the patient's own language, which matters in obesity trials where comorbidities, concomitant medications, and protocol complexity create eligibility barriers that broad outreach handles poorly.

With Patiro's model, sites only receive actionable, medically-vetted referrals. Digital flows capture the data the study team needs early, then clinical staff pressure-test eligibility before anything reaches the site. That protects coordinator capacity and reduces the screen fail rates that follow when BMI is treated as the only gating factor.

Patiro's pay-per-enrolled-patient model ensures a premium service with minimal financial risk for sponsors and keeps budget exposure tied to results rather than activity. Patiro is a strong fit when sponsors need predictable enrollment across multiple sites, clean handoffs into site workflows, and global reach with hyper-local execution across diverse patient populations.

‍

2. IQVIA

IQVIA brings global infrastructure and real-world data assets that can support more specific metabolic targeting compared to broad outreach alone. Their scale helps when a sponsor is coordinating across many geographies and needs consistent process, reporting, and governance. They also bring experience working with physician networks and health record-driven insights to support targeting and follow-up.

IQVIA can be an ideal fit for large, multi-country obesity programs where recruitment needs to integrate with broader clinical operations and analytics, and where demographic target oversight creates reporting pressure.

‍

3. ICON plc

ICON is a full-service CRO with patient recruitment capabilities suited to complex metabolic and weight-management protocols. Recruitment is treated as part of delivery, not as a standalone media effort. That matters when inclusion criteria shift mid-study and the plan needs to adapt without disrupting timelines.

ICON’s value often shows up at the interface between feasibility, site support, and recruitment planning, especially when BMI based trial enrollment is only the opening filter and the real attrition happens in labs, comorbidities, and medication constraints.

ICON may be a good option when sponsors who want recruitment tightly coupled with CRO delivery, especially for multi-cohort protocols, demanding visit schedules, or elevated screen fail risk.

‍

4. Labcorp Drug Development

Labcorp Drug Development combines site network reach with recruitment execution. That can help when obesity trials need consistent screening pathways and retention support across many locations. Their breadth is useful for programs where central labs, patient materials, and site operations need to move in lockstep, not as separate workstreams.

They are experienced with the practical details that tend to slow teams down: IRB and EC-ready materials, culturally appropriate messaging, and managing the patient path from first contact through participation. Labcorp is ideal for programs that need integrated operational support across sites and patient-facing workflows, not only lead generation.

‍

5. Parexel International

Parexel has deep experience in obesity and metabolic development programs, including approaches that combine digital recruitment with community-level access. That mix can matter when obesity study patient recruitment needs to reflect real epidemiology across race, ethnicity, geography, and socioeconomic status under current FDA expectations.

Parexel is also commonly considered for rescue situations when early enrollment underperforms and a program needs corrective action without a long reset.

Paraxel may be a good fit in studies where diversity targets and retention risk carry as much weight as top-of-funnel volume, and where the sponsor wants a partner that can intervene quickly if enrollment slips.

‍

6. Syneos Health

Syneos Health combines clinical services with commercial insight. That can help when weight loss clinical trial recruitment requires careful positioning and community reach beyond generic ads. Their approach often includes site and physician relationships alongside broader outreach, which can reduce friction when leads transition into site prescreening.

Their strength is often in upfront planning, including choosing engagement methods that match where patients actually receive obesity care.

Syneos may be the right choice for sponsors who want recruitment planning grounded in market reality, including who manages obesity in the community and what language drives qualified engagement.

‍

7. Clinical Trial Media (CTM)

Clinical Trial Media is known for performance marketing at scale across digital channels. For obesity clinical trial recruitment, that can help when speed and volume are priorities and there is a tight optimization loop in place.

High volume can become a liability in obesity if it is not paired with strong prescreen logic and clear data requirements at intake. CTM tends to perform best when the protocol team has clarity on qualification checkpoints before sites see referrals. CTM may be a fit for programs that need rapid top-of-funnel expansion and have site capacity to handle higher lead flow with prescreen checkpoints.

‍

8. Altasciences

Altasciences is known for clinical research services with access to volunteer populations including participants with elevated BMI for certain study types. When protocol fit is right, database-driven recruitment can shorten timelines because the first pass at eligibility happens against known profiles rather than broad public outreach.

Their site-centric orientation can also support consistent screening and retention behaviors and it maybe be a strong fit for early-phase or specialty designs that benefit from existing volunteer databases, especially where BMI and metabolic markers drive screening.

‍

9. Antidote

Antidote operates as a full-service recruitment partner combining digital outreach with a partner network to reach obesity patients outside of site databases. For obesity clinical trial recruitment, their model is relevant when sponsors need both broad patient discovery and structured pre-screening in one relationship, and where controlling referral quality before intake reaches sites is a priority.

Antidote may be a fit for obesity programs where sponsors want digital reach and pre-screened referrals managed through a single recruitment partner, particularly when site capacity and coordinator bandwidth are constraints.

‍

10. TrialX

TrialX operates as a platform and recruitment partner that connects people to clinical trials. Their value in obesity clinical trial recruitment is often tied to database reach and targeted outreach linked to specific criteria. For programs that need ongoing enrollment across multiple sites, access to pre-identified participants can reduce reliance on broad awareness campaigns.

TrialX may be ideal for studies that benefit from database-driven matching and ongoing participant engagement, especially when eligibility can be translated into clear prescreen questions for fast triage.

‍

Why Obesity Clinical Trial Recruitment Can Be Challenging

Obesity trials look high prevalence on paper. In operations, the eligible population is usually a slice of a slice.

BMI based trial enrollment is the obvious starting point, but BMI rarely determines final eligibility by itself. Protocols narrow the pool quickly with A1c ranges, blood pressure parameters, hepatic and renal labs, prior bariatric procedures, medication history including GLP-1 use and washout constraints, and comorbidity patterns that are common in the real world but exclusionary in protocol logic.

Screen fail management becomes a recruitment problem, not only a site problem. Campaigns optimized for clicks rather than qualification waste coordinator time on repeated prescreens, manual data clean-up, and rescheduling.

Diversity targets change how teams recruit, not just what they report. FDA expectations now oblige sponsors to file demographic enrollment targets. That pushes teams toward outreach models that can engage underrepresented groups in a documented, repeatable way. Obesity is also tied to social determinants of health, so access barriers such as transportation, time off work, childcare, and language show up early as no-shows and discontinuations if the recruitment plan ignores them.

Newer development programs also raise specificity. Recent trials are evaluating combinations such as NT-0796 with semaglutide, which increases the need to recruit adults with particular metabolic profiles and medication histories. In that environment, interested and eligible are very different categories.

‍

How to Choose the Right Obesity Clinical Trial Recruitment Partner

Prioritize Therapeutic Area Experience

Ask for obesity-specific experience, not metabolic as a catch-all. Look for evidence that the partner understands the common failure modes: not enough qualified leads, screen failures driven by high-prevalence comorbidities, and retention friction from visit schedules and lifestyle requirements.

Request proof that eligibility can be translated into campaign logic and prescreen workflows. Case studies should show more than enrolled totals. Ask about qualification rate, where screen fails clustered, and what changed after optimization.

If the program includes add-on therapy, combination therapy, or a run-in period, discuss it early. Teams without that experience often underestimate time-to-randomization and overestimate conversion from lead to randomized participant.

‍

Evaluate Digital and Community Reach Strategies

Digital can work for some obesity studies, but it is rarely sufficient when demographic enrollment targets require reaching patients who do not respond to standard ads. Strong partners combine search and social digital campaignswith community partnerships, referral pathways, and tailored messaging that reflects how different populations seek obesity care.

Also pay attention to how BMI based trial enrollment is communicated. Overly direct messaging attracts high volume with poor alignment. Overly vague messaging suppresses response. A workable version supports self-selection, collects prescreen data early, and stays within IRB and EC expectations.

Ask where the partner expects eligibility to break. If they cannot name likely friction points such as current GLP-1 use, diabetes thresholds, uncontrolled hypertension, prior procedures, or unwillingness to pause medications, they are running a generic playbook.

‍

Assess Data-Driven Decisions and Compliance Discipline

Data only matters if it changes decisions. Ask which inputs drive targeting and optimization, such as site performance, lead quality by channel, geographic concentration, and prescreen failure reasons, and how often adjustments are made. Obesity recruitment needs active management because lead quality shifts as soon as the easiest audiences saturate.

Compliance needs to be visible in workflow, not just in an SOP library. Review how the partner handles IRB and EC submissions, version control, adverse event language in patient communications when applicable, and privacy expectations around prescreen data. Multi-region work also requires careful language variants and culturally appropriate materials without introducing approval delays.

A consultative posture is a practical advantage. Partners who will challenge assumptions without turning it into a debate prevent avoidable failure modes in obesity study patient recruitment, especially when enrollment is tied to public commitments on timelines and diversity.

‍

Final Thoughts on the Best Obesity Clinical Trial Recruitment Companies

The best obesity clinical trial recruitment partners are not the ones that generate the most leads. They protect sites from avoidable noise, translate complex eligibility into workable prescreen flows, and document progress toward demographic targets while enrollment is underway.

When picking partners for weight loss clinical trial recruitment, prioritize obesity-specific experience, a plan that includes both digital and community reach, and a compliance process that supports iteration without adding delay. Obesity trials can enroll quickly, but only when BMI based trial enrollment is treated as the beginning of the funnel, not the whole funnel.